“…With regard to SHK-specific inhibitors, there is also a paucity of knowledge on how agonists and antagonists bind to some target sites within SHK proteins; increased knowledge in this area would be beneficial for structure-based drug design strategies, which are currently less popular but nonetheless worthy of continued pursuance. Whilst the structures and functions of many individual SHK domains, domain hybrids and multi-domain SHKs are known, including natively soluble SHKs that lack transmembrane segments [ 67 , 68 , 69 , 70 , 71 , 72 ], all of which have contributed significantly to knowledge of these proteins, there remains a lack of structural data on full-length membrane SHKs which results in part from the technical challenges associated with their purification as intact active membrane proteins in sufficient milligram quantities for elucidation of their three-dimensional structures by crystallisation or other methods [ 73 ]. However, these challenges are being overcome and in this Review, we describe some of the emerging successes in the overexpression and purification of full-length active membrane SHKs, the methods used for their solubilisation and reconstitution using detergents, amphipols, liposomes, and nanodiscs, and some of the consequent successes in structural and ligand binding studies, thereby expanding upon and complementing other Reviews of SHKs to date, which have focused less on studies of full-length purified proteins.…”